Effects of dapagliflozin on inflammatory and apoptotic markers in rats exposed to cyclophosphamide-induced hepatotoxicity: comparison with silymarin
DOI:
https://doi.org/10.60988/p.v37i2S.245Keywords:
cyclophosphamide; dapagliflozin; silymarin; inflammation; apoptosisAbstract
Cyclophosphamide (CPA) is a widely used chemotherapeutic agent; however, its clinical utility is constrained by dose-dependent hepatotoxicity. This study evaluated the hepatoprotective effects of dapagliflozin (DAPA), a sodium-glucose co-transporter 2 (SGLT2) inhibitor with known anti-inflammatory properties, in comparison to silymarin (SILY); a well-established hepatoprotective flavonoid. Fifty Wistar rats were randomly assigned to five groups: (i) negative control, (ii) vehicle control receiving 2% sodium carboxymethyl cellulose, (iii) CPA-treated (30 mg/kg/day), (iv) CPA + DAPA (3 mg/kg/day), and (v) CPA + SILY (200 mg/kg/day). All treatments were administered for ten consecutive days. CPA administration significantly elevated hepatic levels of tumor necrosis factor alpha (TNF-α; a pro-inflammatory cytokine), while reducing interleukin-10 (IL-10; an anti-inflammatory mediator), thereby aggravating liver injury. DAPA was more effective than SILY in attenuating inflammation and restoring IL-10 levels. Furthermore, CPA markedly increased expression of caspase-3 (a pro-apoptotic marker) and decreased B-cell lymphoma 2 (BCL-2; an anti-apoptotic protein), indicating enhanced apoptotic activity. Both DAPA and SILY ameliorated these apoptotic changes, with DAPA exerting a more pronounced anti-apoptotic effect. In conclusion, DAPA demonstrated superior hepatoprotective efficacy compared to SILY, characterized by stronger anti-inflammatory and anti-apoptotic actions. These findings support the potential of DAPA as a therapeutic candidate for CPA-induced hepatotoxicity, warranting further investigation into its clinical applicability and possible synergistic use in combination therapies.
References
1. Delahousse J., Molina L., Paci A. Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities. Cancer Lett. 598, 217119, 2024. DOI: 10.1016/j.canlet.2024.217119
2. El-Beheiry K.M., El-Sayed El-Sayad M., El-Masry T.A., Elsisi A.E. Combination of metformin and hesperidin mitigates cyclophosphamide-induced hepatotoxicity. Emerging role of PPAR-γ/Nrf-2/NF-κB signaling pathway. Int. Immunopharmacol. 117, 109891, 2023. DOI: 10.1016/j.intimp.2023.109891
3. Akamo A.J., Rotimi S.O., Akinloye D.I., Ugbaja R.N., Adeleye O.O., Dosumu O.A., et al. Naringin prevents cyclophosphamide-induced hepatotoxicity in rats by attenuating oxidative stress, fibrosis, and inflammation. Food Chem. Toxicol. 153, 112266, 2021. DOI: 10.1016/j.fct.2021.112266
4. Sherif I.O. The effect of natural antioxidants in cyclophosphamide-induced hepatotoxicity: role of Nrf2/HO-1 pathway. Int. Immunopharmacol. 61, 29–36, 2018. DOI: 10.1016/j.intimp.2018.05.007
5. Abd-Eldayem A.M., Makram S.M., Messiha B.A.S., Abd-Elhafeez H.H., Abdel-Reheim M.A. Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax. Sci. Rep. 14(1), 7434, 2024. DOI: 10.1038/s41598-024-57300-x
6. Castoldi G., Carletti R., Ippolito S., Colzani M., Barzaghi F., Stella A., et al. Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy. Acta Diabetol. 58(8), 1059–1070, 2021. DOI: 10.1007/s00592-021-01681-2
7. Mohammed A.H., Al-Khishali D.K., Al-Shawi N.N.: Anti-oxidant effect of silymarin against DDT-induced nephrotoxicity in rats. Karbala J. Pharm. Sci. 4(4), 136–144, 2013.
8. Patwa J., Khan S., Jena G. Nicotinamide attenuates cyclophosphamide-induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis. J. Biochem. Mol. Toxicol. 34(10), e22558, 2020. DOI: 10.1002/jbt.22558
9. Said Ahmed W.M., Soliman A., Ahmed Amer A.E., El Shahat R.M., Amin M.M., Taha R.S., et al. Effect of dapagliflozin against NAFLD and dyslipidemia in type 2 diabetic albino rats: possible underlying mechanisms. Eur. Rev. Med. Pharmacol. Sci. 27(17), 8101–8109, 2023. DOI: 10.26355/eurrev_202309_33570
10. Jalali S.M., Najafzadeh H., Bahmei S. Protective role of silymarin and D-penicillamine against lead-induced liver toxicity and oxidative stress. Toxicol. Ind. Health 33(6), 512–518, 2017. DOI: 10.1177/0748233716685660
